Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 493-498

  Walters, Christen L ^a   Arend, Rebecca C ^a   Armstrong, Deborah K ^b   Naumann, R Wendel ^c   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Antifolate receptor antibodies; Folate chemotherapy conjugates; Thymidylate synthase inhibitors

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ANTINEOPLASTIC AGENT; BGC 945; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; FARLETUZUMAB; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR ALPHA ANTAGONIST; FOLIC ACID; FOLIC ACID ANTAGONIST; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PLATINUM; PLEVITREXED; RADIOISOTOPE; RECEPTOR ANTIBODY; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; VINTAFOLIDE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER PATIENT; CELL PROLIFERATION; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENTARITY DETERMINING REGION; CROSS REACTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY PROXIMAL TUBULE; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PRIMATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TROPHOBLAST; UNSPECIFIED SIDE EFFECT;

EID: 84886092119     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.080     Document Type: Review

References (63)

1. National Cancer Institute Ovarian cancer 2013 [National Cancer Institute]
2. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
3. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
4. S. Vaughan, J.I. Coward, and R.C. Bast Jr. Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 2011 719 725
5. A.R. Carroll, R.L. Coleman, and A.K. Sood Therapeutic advances in women's cancers Front Biosci (Schol Ed) 3 2011 82 97
6. F. Heitz, P. Harter, and J. Barinoff Bevacizumab in the treatment of ovarian cancer Adv Ther 29 2012 723 735
7. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
8. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
9. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and peritoneal cancer v 3.2012 2012 [National Comprehensive Cancer Network]
10. H.X. Chen, R.E. Gore-Langton, and B.D. Cheson Clinical trials referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab Oncology (Williston Park) 15 2001 1017 [1020, 1023-17, 1020, 1026]
11. L.E. Kelemen, M.T. Goodman, and V. McGuire Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium Cancer Epidemiol Biomarkers Prev 19 2010 1822 1830
12. S.W. Choi, and J.B. Mason Folate and carcinogenesis: an integrated scheme J Nutr 130 2000 129 132
13. S. Markert, S. Lassmann, and B. Gabriel Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue Anticancer Res 28 2008 3567 3572
14. J.H. Park, S. Lee, J.H. Kim, K. Park, K. Kim, and I.C. Kwon Polymeric nanomedicine for cancer therapy Prog Polym Sci 33 2008 113 137
15. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid N Engl J Med 238 1948 787 793
16. J.T. Fox, and P.J. Stover Folate-mediated one-carbon metabolism Vitam Horm 79 2008 1 44
17. D. Cardinale, G. Guaitoli, and D. Tondi Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase Proc Natl Acad Sci U S A 108 2011 E542 E549
18. R. Hertz, M.C. Li, and D.B. Spencer Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma Proc Soc Exp Biol Med 93 1956 361 366
19. C. Heidelberger Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges - G.H.A. Clowes Memorial Lecture Cancer Res 30 1970 1549 1569
20. P.A. Vasey, L. McMahon, J. Paul, N. Reed, and S.B. Kaye A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer Br J Cancer 89 2003 1843 1848
21. A.B. Miller, D.J. Klaassen, and D.A. Boyes Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer Can Med Assoc 123 1980 365 371
22. J. Doroshow Intraperitoneal chemotherapy with cisplatin and 5-fluorouracil: an active regimen for refractory ovarian cancer 5, 117 Proceedings of the American Society of Clinical Oncology 1986
23. Fiorentino M. 5-Fluorouracil and platin as second line in ovarian cancer. Second International Symposium on "Multimodality of treatment in Ovarian Cancer", September 24-26, 1987, Genoa, Italy, 1987.
24. D.S. Miller, J.A. Blessing, and C.N. Krasner Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 2009 2686 2691
25. A.R. Hagemann, I. Zieghelboim, and A.P. Novetsky Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer J Clin Oncol 30 Suppl. abstr 5013 2012
26. D.D. Gibbs, D.S. Theti, and N. Wood BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors Cancer Res 65 2005 11721 11728
27. L.R. Celeste, G. Chai, M. Bielak, W. Minor, L.L. Lovelace, and L. Lebioda Mechanism of N10-formyltetrahydrofolate synthetase derived from complexes with intermediates and inhibitors Protein Sci 21 2012 219 228
28. Clinicaltrials.gov FR in stored plasma. clinicaltrials.gov NCT00787514: Royal Marsden NHS Foundation Trust 2008
29. R. Plummer, C. Rees, and A. Hughes A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor Clin Cancer Res 9 2003 1313 1322
30. Clinicaltrials.gov. ZD9331 With or without topotecan in treating patients with refractory or recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. clinicaltrials.gov: AstraZeneca, 2011.
31. A.C. Antony Folate receptors Annu Rev Nutr 16 1996 501 521
32. S. Rijnboutt, G. Jansen, G. Posthuma, J.B. Hynes, J.H. Schornagel, and G.J. Strous Endocytosis of GPI-linked membrane folate receptor-alpha J Cell Biol 132 1996 35 47
33. H. Elnakat, and M. Ratnam Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy Adv Drug Deliv Rev 56 2004 1067 1084
34. S.D. Weitman, A.G. Weinberg, L.R. Coney, V.R. Zurawski, D.S. Jennings, and B.A. Kamen Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis Cancer Res 52 1992 6708 6711
35. L.E. Kelemen The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119 2006 243 250
36. F. Shen, H. Wang, X. Zheng, and M. Ratnam Expression levels of functional folate receptors α and β are related to the number of N-glycosylated sites Biochem J 327 pt 3 1997 759 764
37. K. Ramamoorthy, S. Potala, and R.S. Verma Insilco analysis of functionally important residues in folate receptors Bioinformation 2 2007 157 162
38. J.A. Reddy, L.S. Haneline, E.F. Srour, A.C. Antony, D.W. Clapp, and P.S. Low Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells Blood 93 1999 3940 3948
39. J.A. Konner, K.M. Bell-McGuinn, and P. Sabbatini Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: a phase I study Clin Cancer Res 16 2010 5288 5295
40. G. Toffoli, C. Cernigoi, A. Russo, A. Gallo, M. Bagnoli, and M. Boiocchi Overexpression of folate binding protein in ovarian cancers Int J Cancer 74 1997 193 198
41. Naumann RW, Coleman RL, Burger RA, et al. A Randomized phase II trial comparing EC145 and Pegylated Liposomal Doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. 43rd Annual Meeting of the Society of Gynecologic Oncology, March 24-27, 2012, Austin, TX 2012.
42. F. Bellati, C. Napoletano, and M.L. Gasparri Monoclonal antibodies in gynecological cancer: a critical point of view Clin Dev Immunol 2011 2011 890758
43. P. Garin-Chesa, I. Campbell, P.E. Saigo, J.L. Lewis Jr., L.J. Old, and W.J. Rettig Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein Am J Pathol 142 1993 557 567
44. W. Ebel, E.L. Routhier, and B. Foley Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha Cancer Immunol 7 2007 6
45. S. Miotti, M. Bagnoli, A. Tomassetti, M.I. Colnaghi, and S. Canevari Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1 J Cell Sci 113 Pt 2 2000 349 357
46. K.R. Kalli MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer Curr Opin Investig Drugs 8 2007 1067 1073
47. P.M. Smith-Jones, N. Pandit-Taskar, and W. Cao Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003 Nucl Med Biol 35 2008 343 351
48. A.J. White, R.L. Coleman, and D.K. Armstrong Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study J Clin Oncol 28 Suppl. 15 2010
49. Clinicaltrials.gov. Effectiveness of MORAb-003 in women with ovarian cancer who have relapsed after platinum-based chemotherapy. clinicaltrials.gov: Morphotek, 2012.
50. Morphotek. Morphotek announces top-line results of a phase III study of farletuzumab in patients with relapsed platinum-sensitive epithelial ovarian cancer. Exton, PA, 1-10-2013.
51. Clinicaltrials.gov. Efficacy and safety of MORAb-003 in subjects with platinum-sensitive ovarian cancer in first relapse. clinicaltrials.gov: Morphotek, 2012.
52. Clinicaltrials.gov. An efficacy and safety study of MORAb-003 in platinum-resistant or refractory relapsed ovarian cancer (FAR-122). clinicaltrials.gov: Morphotek, 2012.
53. C.P. Leamon, and J.A. Reddy Folate-targeted chemotherapy Adv Drug Deliv Rev 56 2004 1127 1141
54. P.M. Lorusso, M.J. Edelman, and S.L. Bever Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors J Clin Oncol 30 2012 4011 4016
55. E. Sausville A phase I study of EC145 administered weeks 1 and 3 of a 4-week cycle in patients with refractory solid tumors J Clin Oncol 25 Suppl. 18 2007
56. Naumann R. A phase II study of EC145 in patients with advanced ovarian cancer. 16th International Meeting of the European Society of Gynaecological Oncology, October 11-14, 2009, Belgrade, Serbia, 2009.
57. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
58. Clinicaltrials.gov Study for women with platinum resistant ovarian cancer evaluating EC145 in combination with Doxil® (PROCEED). clinicaltrials.gov 2012 Washington University School of Medicine
59. R.J. Lee, and P.S. Low Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis J Biol Chem 269 1994 3198 3204
60. S. Wang, R.J. Lee, G. Cauchon, D.G. Gorenstein, and P.S. Low Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol Proc Natl Acad Sci U S A 92 1995 3318 3322
61. G.M. van Dam, G. Themelis, and L.M. Crane Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results Nat Med 17 2011 1315 1319
62. C.P. Leamon, M.A. Parker, and I.R. Vlahov Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical Bioconjug Chem 13 2002 1200 1210
63. J.T. Symanowski, A.H. Maurer, N.P. Naumann, D. Shah, and R.A. Morgenstern Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer J Clin Oncol 28 Suppl. 15 2010